Low Stability of Integrin-Binding Deficient Mutant of FGF1 Restricts Its Biological Activity

Cells. 2019 Aug 15;8(8):899. doi: 10.3390/cells8080899.

Abstract

Fibroblast growth factor 1 (FGF1) has been shown to interact with integrin αvβ3 through a specific binding site, involving Arg35 residue. The FGF1 mutant (R35E) with impaired integrin binding was found to be defective in its proliferative response, although it was still able to interact with FGF receptors (FGFR) and heparin and induce the activation of downstream signaling pathways. Here, we demonstrate that the lack of mitogenic potential of R35E mutant is directly caused by its decreased thermodynamic stability and susceptibility to proteolytic degradation. Introduction of three stabilizing mutations into R35E variant compensated the effect of destabilizing R35E mutation and restored the proliferation potential of FGF1. Moreover, the stabilized R35E variant regained both anti-apoptotic and wound healing activities, while remaining defective in binding to integrin αvβ3. Our results suggest that the thermodynamic stability and resistance to degradation, rather than the interaction with integrin are required for mitogenic response of FGF1.

Keywords: anti-apoptotic activity; fibroblast growth factor 1; integrin αvβ3; mitogenic activity; protein stability; protein-protein interaction; proteolytic degradation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Binding Sites
  • Fibroblast Growth Factor 1 / chemistry*
  • Fibroblast Growth Factor 1 / genetics
  • Heparin / chemistry
  • Humans
  • Integrin alphaVbeta3 / chemistry
  • Integrin alphaVbeta3 / metabolism*
  • Kinetics
  • Mice
  • Mutation
  • NIH 3T3 Cells
  • Protein Binding
  • Protein Stability*
  • Proteolysis*
  • Receptors, Fibroblast Growth Factor / chemistry

Substances

  • Integrin alphaVbeta3
  • Receptors, Fibroblast Growth Factor
  • Fibroblast Growth Factor 1
  • Heparin